Xilio Therapeutics, Inc. financial data

Symbol
XLO on Nasdaq
Industry
Pharmaceutical Preparations
Location
828 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 208 % -59.7%
Debt-to-equity 163 % +358%
Return On Equity -215 % -105%
Return On Assets -81.5 % -5.65%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44M shares +59.6%
Common Stock, Shares, Outstanding 44M shares +59.7%
Entity Public Float 67.7M USD -3.84%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 63.5M shares +131%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.26M USD
Research and Development Expense 44.1M USD -20.4%
General and Administrative Expense 24.7M USD -14.3%
Operating Income (Loss) -65.1M USD +22.7%
Nonoperating Income (Expense) 2.28M USD -22.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -62.8M USD +22.7%
Earnings Per Share, Basic -1.72 USD/shares +41.9%
Earnings Per Share, Diluted -1.72 USD/shares +41.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.3M USD +2.49%
Assets, Current 63.3M USD -1.82%
Property, Plant and Equipment, Net 4.85M USD -23.9%
Operating Lease, Right-of-Use Asset 4.73M USD -9.87%
Other Assets, Noncurrent 92K USD -53.3%
Assets 74.7M USD -4.09%
Accounts Payable, Current 972K USD -34.6%
Accrued Liabilities, Current 9.79M USD +4.14%
Liabilities, Current 38M USD +125%
Operating Lease, Liability, Noncurrent 7.26M USD -13.7%
Other Liabilities, Noncurrent 7K USD -91.5%
Liabilities 53.7M USD +112%
Retained Earnings (Accumulated Deficit) -371M USD -20.4%
Stockholders' Equity Attributable to Parent 21M USD -60%
Liabilities and Equity 74.7M USD -4.09%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD +58.4%
Net Cash Provided by (Used in) Financing Activities 954K USD
Net Cash Provided by (Used in) Investing Activities -170K USD +33.1%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 44M shares +59.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.55M USD +64.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63M USD +2.74%
Interest Paid, Excluding Capitalized Interest, Operating Activities 62K USD -70.3%
Deferred Tax Assets, Valuation Allowance 93M USD +30.9%
Deferred Tax Assets, Gross 96M USD +29%
Operating Lease, Liability 9.19M USD -9.08%
Depreciation 400K USD -20%
Payments to Acquire Property, Plant, and Equipment 170K USD -33.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.8M USD +22.7%
Lessee, Operating Lease, Liability, to be Paid 11.7M USD -12.6%
Property, Plant and Equipment, Gross 11.9M USD -1.44%
Operating Lease, Liability, Current 1.15M USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.79M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.73M USD +2.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.53M USD -23.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.84M USD +3.03%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.89M USD +2.99%
Additional Paid in Capital 392M USD +8.68%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 443K USD -11.2%
Deferred Tax Assets, Net of Valuation Allowance 2.98M USD -12.6%
Share-based Payment Arrangement, Expense 6.85M USD -5.77%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%